Human VEGF 183 / VEGF-A Recombinant Protein(Discontinued)
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
Amount : | 50 µg |
Purification : | > 95 % as determined by SDS-PAGE. |
Content : | Formulation Lyophilized from sterile pH 7.92 100 mM glycine , 10 mM NaCl. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
Storage condition : | Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
AA sequence : | Met1-Arg209 |
Alternative Name : | MVCD1 Protein, VEGF Protein, VEGF165 Protein, VPF Protein, |
Source : Baculovirus-Insect Cells
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor. Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy
Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 50-210 ng/mL.
Endotoxin :< 1.0 EU per µg protein as determined by the LAL method.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
There are currently no product reviews
|